New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
15:34 EDTARNAArena Pharmaceuticals drops after CHMP issues recommendations
The stock is down over 5.4% at time of writing, edging toward session lows. At the current price of $9.87, next support is at $9.47. Resistance is at the 10-day moving average, last at $10.03.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
08:18 EDTARNAArena press release lacking key data, TheStreet's Feuerstein says
Subscribe for More Information
October 28, 2014
18:25 EDTARNAArena Pharmaceuticals, Eisai study meets primary safety objective
Eisai and Arena Pharmaceuticals announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the short-term combination of lorcaserin plus phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events compared to therapy with lorcaserin alone. The coadministration of lorcaserin and phentermine for weight management is investigational. The efficacy and safety of coadministration of lorcaserin and other weight loss products such as phentermine have not been established.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use